Molecules and Cells

Korean Society for Molecular and Cellular Biology (한국분자세포생물학회)
권호 표지
DOI QR코드

DOI QR Code

Rocaglamide-A Potentiates Osteoblast Differentiation by Inhibiting NF-κB Signaling

  • Li, Aiguo (Department of Orthopedic Surgery, The First Affiliated Hospital of Xinxiang Medical University) ;
  • Yang, Libin (Department of Orthopedic Surgery, The First Affiliated Hospital of Xinxiang Medical University) ;
  • Geng, Xiaolin (Department of Orthopedic Surgery, The First Affiliated Hospital of Xinxiang Medical University) ;
  • Peng, Xingmei (Department of Oncology, The Third Affiliated Hospital of Xinxiang Medical University) ;
  • Lu, Tan (Department of Orthopedic Surgery, The First Affiliated Hospital of Xinxiang Medical University) ;
  • Deng, Yanjun (Department of Orthopedic Surgery, The First Affiliated Hospital of Xinxiang Medical University) ;
  • Dong, Yuzheng (Department of Orthopedic Surgery, The First Affiliated Hospital of Xinxiang Medical University)
  • Received : 2014.12.29
  • Accepted : 2015.09.01
  • Published : 2015.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Rheumatoid arthritis is a chronic inflammatory disease that leads to bone and cartilage erosion. The inhibition of osteoblast differentiation by the inflammatory factor TNF-${\alpha}$ is critical for the pathogenesis of rheumatoid arthritis. To modulate TNF-${\alpha}$ mediated inhibition of osteoblast differentiation is required to improve therapeutic efficacy of rheumatoid arthritis. Here, we explored the potential role of rocaglamide-A, a component of Aglaia plant, in osteoblast differentiation. Rocaglamide-A prevented TNF-${\alpha}$ mediated inhibition of osteoblast differentiation, and promoted osteoblast differentiation directly, in both C2C12 and primary mesenchymal stromal cells. Mechanistically, Rocaglamide-A inhibited the phosphorylation of NF-${\kappa}B$ component p65 protein and the accumulation of p65 in nucleus, which resulted in the diminished NF-${\kappa}B$ responsible transcriptional activity. Oppositely, overexpression of p65 reversed rocaglamide-A's protective effects on osteoblast differentiation. Collectively, rocaglamide-A protected and stimulated osteoblast differentiation via blocking NF-${\kappa}B$ pathway. It suggests that rocaglamide-A may be a good candidate to develop as therapeutic drug for rheumatoid arthritis associated bone loss diseases.

Keywords

References

  1. Azuma, Y., Kaji, K., Katogi, R., Takeshita, S. and Kudo, A. (2000) Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J. Biol. Chem. 275, 4858-4864. https://doi.org/10.1074/jbc.275.7.4858
  2. Baumann, B., Bohnenstengel, F., Siegmund, D., Wajant, H., Weber, C., Herr, I., Debatin, K.M., Proksch, P., and Wirth, T. (2002). Rocaglamide derivatives are potent inhibitors of NF-kappa B activation in T-cells. J. Biol. Chem. 277, 44791-44800. https://doi.org/10.1074/jbc.M208003200
  3. Bohnenstengel, F.I., Steube, K.G., Meyer, C., Nugroho, B.W., Hung, P.D., Kiet, L.C., and Proksch, P. (1999). Structure activity relationships of antiproliferative rocaglamide derivatives from Aglaia species (Meliaceae). Z. Naturforsch. C 54, 55-60.
  4. Canalis, E. (1987) Effects of tumor necrosis factor on bone formation in vitro. Endocrinology 121, 1596-1604. https://doi.org/10.1210/endo-121-5-1596
  5. Chang, J., Wang, Z., Tang, E., Fan, Z., McCauley, L., Franceschi, R., Guan, K., Krebsbach, P.H., and Wang, C.Y. (2009). Inhibition of osteoblastic bone formation by nuclear factor-kappaB. Nat. Med. 15, 682-689. https://doi.org/10.1038/nm.1954
  6. Chang, J., Liu, F., Lee, M., Wu, B., Ting, K., Zara, J.N., Soo, C., Al Hezaimi, K., Zou, W., Chen, X., et al. (2013). NF-kappaB inhibits osteogenic differentiation of mesenchymal stem cells by promoting beta-catenin degradation. Proc. Natl. Acad. Sci. USA 110, 9469-9474. https://doi.org/10.1073/pnas.1300532110
  7. Collett, G.P. and Campbell, F.C. (2006) Overexpression of p65/RelA potentiates curcumin-induced apoptosis in HCT116 human colon cancer cells. Carcinogenesis 27, 1285-1291. https://doi.org/10.1093/carcin/bgi368
  8. Dreyer, M., Nugroho, B.W., Bohnenstengel, F.I., Ebel, R., Wray, V., Witte, L., Bringmann, G., Muhlbacher, J., Herold, M., Hung, P.D., et al. (2001). New insecticidal rocaglamide derivatives and related compounds from Aglaia oligophylla. J. Nat. Prod. 64, 415-420. https://doi.org/10.1021/np000123x
  9. Goldring, S.R. and Gravallese, E.M. (2000) Pathogenesis of bone erosions in rheumatoid arthritis. Curr. Opin. Rheumatol 12, 195-199. https://doi.org/10.1097/00002281-200005000-00006
  10. Huang, W., Yang, S., Shao, J. and Li, Y.P. (2007) Signaling and transcriptional regulation in osteoblast commitment and differentiation. Front. Biosci. 12, 3068-3092. https://doi.org/10.2741/2296
  11. Kaneko, H., Arakawa, T., Mano, H., Kaneda, T., Ogasawara, A., Nakagawa, M., Toyama, Y., Yabe, Y., Kumegawa, M. and Hakeda, Y. (2000). Direct stimulation of osteoclastic bone resorption by bone morphogenetic protein (BMP)-2 and expression of BMP receptors in mature osteoclasts. Bone 27, 479-486. https://doi.org/10.1016/S8756-3282(00)00358-6
  12. Karsenty, G., Kronenberg, H.M. and Settembre, C. (2009) Genetic control of bone formation. Annu. Rev. Cell Dev. Biol. 25, 629-648. https://doi.org/10.1146/annurev.cellbio.042308.113308
  13. Kim, S., Salim, A.A., Swanson, S.M., and Kinghorn, A.D. (2006). Potential of cyclopenta[b]benzofurans from Aglaia species in cancer chemotherapy. Anticancer Agents Med. Chem. 6, 319-345. https://doi.org/10.2174/187152006777698123
  14. Lee, S.K., Cui, B., Mehta, R.R., Kinghorn, A.D., and Pezzuto, J.M. (1998). Cytostatic mechanism and antitumor potential of novel 1H-cyclopenta[b]benzofuran lignans isolated from Aglaia elliptica. Chem. Biol. Interact. 115, 215-228. https://doi.org/10.1016/S0009-2797(98)00073-8
  15. Lee, H.L., Yi, T., Woo, K.M., Ryoo, H.M., Kim, G.S., and Baek, J.H. (2010). Msx2 mediates the inhibitory action of TNF-alpha on osteoblast differentiation. Exp. Mol. Med. 42, 437-445. https://doi.org/10.3858/emm.2010.42.6.045
  16. Li, Y.C., Ross, J., Scheppler, J.A., and Franza, B.R., Jr. (1991). An in vitro transcription analysis of early responses of the human immunodeficiency virus type 1 long terminal repeat to different transcriptional activators. Mol. Cell Biol. 11, 1883-1893. https://doi.org/10.1128/MCB.11.4.1883
  17. Li, Y., Li, A., Strait, K., Zhang, H., Nanes, M.S., and Weitzmann, M.N. (2007). Endogenous TNFalpha lowers maximum peak bone mass and inhibits osteoblastic Smad activation through NF-kappaB. J. Bone Miner Res. 22, 646-655. https://doi.org/10.1359/jbmr.070121
  18. McInnes, I.B., and Schett, G. (2007). Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7, 429-442. https://doi.org/10.1038/nri2094
  19. Mosmann, T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55-63. https://doi.org/10.1016/0022-1759(83)90303-4
  20. Mukai, T., Otsuka, F., Otani, H., Yamashita, M., Takasugi, K., Inagaki, K., Yamamura, M. and Makino, H. (2007). TNF-alpha inhibits BMP-induced osteoblast differentiation through activating SAPK/JNK signaling. Biochem. Biophys. Res. Commun. 356, 1004-1010. https://doi.org/10.1016/j.bbrc.2007.03.099
  21. Nanjundaiah, S.M., Astry, B. and Moudgil, K.D. (2013) Mediators of inflammation-induced bone damage in arthritis and their control by herbal products. Evid. Based Complement Alternat. Med. 2013, 518094.
  22. Proksch, P., Giaisi, M., Treiber, M.K., Palfi, K., Merling, A., Spring, H., Krammer, P.H. and Li-Weber, M. (2005). Rocaglamide derivatives are immunosuppressive phytochemicals that target NF-AT activity in T cells. J. Immunol. 174, 7075-7084. https://doi.org/10.4049/jimmunol.174.11.7075
  23. Redlich, K., Hayer, S., Ricci, R., David, J.P., Tohidast-Akrad, M., Kollias, G., Steiner, G., Smolen, J.S., Wagner, E.F. and Schett, G. (2002). Osteoclasts are essential for TNF-alpha-mediated joint destruction. J. Clin. Invest. 110, 1419-1427. https://doi.org/10.1172/JCI0215582
  24. Smucker, J.D., Rhee, J.M., Singh, K., Yoon, S.T., and Heller, J.G. (2006). Increased swelling complications associated with off-label usage of rhBMP-2 in the anterior cervical spine. Spine 31, 2813-2819. https://doi.org/10.1097/01.brs.0000245863.52371.c2
  25. Stanford, C.M., Jacobson, P.A., Eanes, E.D., Lembke, L.A. and Midura, R.J. (1995) Rapidly forming apatitic mineral in an osteoblastic cell line (UMR 106-01 BSP). J. Biol. Chem. 270, 9420-9428. https://doi.org/10.1074/jbc.270.16.9420
  26. Steer, J.H., Kroeger, K.M., Abraham, L.J. and Joyce, D.A. (2000). Glucocorticoids suppress tumor necrosis factor-alpha expression by human monocytic THP-1 cells by suppressing transactivation through adjacent NF-kappa B and c-Jun-activating transcription factor-2 binding sites in the promoter. J. Biol. Chem. 275, 18432-18440. https://doi.org/10.1074/jbc.M906304199
  27. Walsh, N.C., Reinwald, S., Manning, C.A., Condon, K.W., Iwata, K., Burr, D.B. and Gravallese, E.M. (2009). Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J. Bone Miner Res. 24, 1572-1585. https://doi.org/10.1359/jbmr.090320
  28. Wong, D.A., Kumar, A., Jatana, S., Ghiselli, G., and Wong, K. (2008). Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of off-label PLIF/TLIF use of bone morphogenetic protein-2 (BMP-2). Spine J. 8, 1011-1018. https://doi.org/10.1016/j.spinee.2007.06.014
  29. Yamazaki, M., Fukushima, H., Shin, M., Katagiri, T., Doi, T., Takahashi, T. and Jimi, E. (2009) Tumor necrosis factor alpha represses bone morphogenetic protein (BMP) signaling by interfering with the DNA binding of Smads through the activation of NF-kappaB. J. Biol. Chem. 284, 35987-35995. https://doi.org/10.1074/jbc.M109.070540
  30. Zaidi, M. (2007) Skeletal remodeling in health and disease. Nat. Med. 13, 791-801. https://doi.org/10.1038/nm1593
  31. Zhu, J.Y., Giaisi, M., Kohler, R., Muller, W.W., Muhleisen, A., Proksch, P., Krammer, P.H. and Li-Weber, M. (2009). Rocaglamide sensitizes leukemic T cells to activation-induced cell death by differential regulation of CD95L and c-FLIP expression. Cell Death Differ. 16, 1289-1299. https://doi.org/10.1038/cdd.2009.42
  32. Zara, J.N., Siu, R.K., Zhang, X., Shen, J., Ngo, R., Lee, M., Li, W., Chiang, M., Chung, J., Kwak, J., et al. (2011). High doses of bone morphogenetic protein 2 induce structurally abnormal bone and inflammation in vivo. Tissue Eng. Part A 17, 1389-1399. https://doi.org/10.1089/ten.tea.2010.0555

Cited by

  1. Pilose antler peptide potentiates osteoblast differentiation and inhibits osteoclastogenesis via manipulating the NF-κB pathway vol.491, pp.2, 2017, https://doi.org/10.1016/j.bbrc.2017.07.091
  2. Effects of tanshinol on markers of bone turnover in ovariectomized rats and osteoblast cultures vol.12, pp.7, 2017, https://doi.org/10.1371/journal.pone.0181175
  3. Occlusal trauma inhibits osteoblast differentiation and bone formation through IKK‐NF‐κB signaling vol.91, pp.5, 2015, https://doi.org/10.1002/jper.18-0710
  4. Prohibitin ligands: a growing armamentarium to tackle cancers, osteoporosis, inflammatory, cardiac and neurological diseases vol.77, pp.18, 2015, https://doi.org/10.1007/s00018-020-03475-1
  5. The interactions between mTOR and NF‐κB: A novel mechanism mediating mechanical stretch‐stimulated osteoblast differentiation vol.236, pp.6, 2015, https://doi.org/10.1002/jcp.30184